Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ningbo Scientz Biotechnology CoBJSE:920685 73 Gross Margin % is 62.73% as of Mar. 2026, which is 5% below its 10-year median of 66.13. GuruFocus rates BJSE:920685 with a GF Score™ of 73/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Ningbo Scientz Biotechnology Co ranks better than 67.54% on this metric.
BJSE:920685's Gross Margin % is ranked better than 67.54% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 52.26
vs BJSE:920685: 63.10
Ningbo Scientz Biotechnology Co had a gross margin of 62.73% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Ningbo Scientz Biotechnology Co (BJSE:920685) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ningbo Scientz Biotechnology Co had a gross margin of 62.73% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ningbo Scientz Biotechnology Co Gross Margin % Related Terms
Ningbo Scientz Biotechnology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Scientz Biotechnology Co Gross Margin % Chart
BJSE:920685 vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Ningbo Scientz Biotechnology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningbo Scientz Biotechnology Co Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ningbo Scientz Biotechnology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ningbo Scientz Biotechnology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ningbo Scientz Biotechnology Co (BJSE:920685) has a Gross Margin % of 62.73% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Ningbo Scientz Biotechnology Co and its competitors. This is near median its historical median of 66.13. Over the past decade, Ningbo Scientz Biotechnology Co's Gross Margin % has ranged from 61.54 to 71.23. According to the industry distribution chart, Ningbo Scientz Biotechnology Co ranks #261 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 32.5%.
Is Ningbo Scientz Biotechnology Co's Gross Margin % too high?
Ningbo Scientz Biotechnology Co's current Gross Margin % of 62.73% is near median its 10-year median of 66.13. Over the past 10 years, this metric has ranged from a low of 61.54 to a high of 71.23. The Medical Devices & Instruments industry median Gross Margin % is 52.26. Ningbo Scientz Biotechnology Co's value of 62.73% is 20% above this industry median. Based on the distribution chart, Ningbo Scientz Biotechnology Co ranks #261 out of 804 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Ningbo Scientz Biotechnology Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Scientz Biotechnology Co's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ningbo Scientz Biotechnology Co ranks #261 out of 804 companies for Gross Margin %. This puts Ningbo Scientz Biotechnology Co in the upper half of its industry. The industry median Gross Margin % is 52.26. Ningbo Scientz Biotechnology Co's value of 62.73% is 20% above this benchmark. Historically, Ningbo Scientz Biotechnology Co's own Gross Margin % has ranged from 61.54 to 71.23 over the past decade. While the company's 10-year median is 66.13 vs. the industry median of 52.26, Ningbo Scientz Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.26, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ningbo Scientz Biotechnology Co's current Gross Margin % of 62.73% is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ningbo Scientz Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningbo Scientz Biotechnology Co's current Gross Margin % is 62.73%, which is near median its own 10-year median of 66.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Scientz Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Scientz Biotechnology Co (BJSE:920685) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥12.18 — trading 23.8% below its estimated fair value. The current Gross Margin % is 62.73%, which is near median its 10-year median of 66.13 and 20% above the Medical Devices & Instruments industry median of 52.26. Ningbo Scientz Biotechnology Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ningbo Scientz Biotechnology Co (BJSE:920685), the current Gross Margin % is 62.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningbo Scientz Biotechnology Co (BJSE:920685) Overvalued in 2026?
Based on GuruFocus' analysis, Ningbo Scientz Biotechnology Co stock appears to be undervalued.
The current stock price of ¥12.18 is trading 23.8% below its estimated GF Value™ of ¥15.99.
GuruFocus considers Ningbo Scientz Biotechnology Co to be Modestly Undervalued.
Key valuation signals for BJSE:920685:
Gross Margin %: 62.73% (near median its 10-year median of 66.13)
GF Value™: ¥15.99 vs. price of ¥12.18 (23.8% below fair value)
Industry Position: 20% above the Medical Devices & Instruments median (#261 of 804)
No single metric tells the full story. See the BJSE:920685 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920685 has been successfully added to your 
